InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,658.00
(
0.32%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.25
(
0.35%
)
Bitcoin
62,744.25
(
-0.48%
)
Post# of 15799
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Atlanta1

Send PM Follow Ignore
Followers 195
Posts 31558
Boards Moderated 3
Alias Born 04/08/2002

Atlanta1

Re: None

Thursday, 06/15/2017 9:15:31 AM

Thursday, June 15, 2017 9:15:31 AM

Post# of 15799

09:12

OPK

Opko Health provides update to the topline data analysis of the Phase 3, double-blind, placebo-controlled study of its investigational long-acting human growth hormone product in adults with growth hormone deficiency (6.52)




http://ih.advfn.com/p.php?pid=nmona&article=75013359&symbol=OPK
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent OPK News
More OPK News
InvestorsHub NewsWire

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Start posting your company's news
Only $200 per official company press release!